Skip to main content
SpringerLink
Log in

Strategies for Quantifying the Relationship between Medications and Suicidal Behaviour

What has been Learned?

  • Current Opinion
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

In recent years there has been considerable concern that certain classes of drugs, for example antidepressants, may increase the risk of suicide. In this current opinion article, we examine the literature on methodological and statistical approaches to the design and analysis of suicidal event studies. Experimental, ecological and observational studies of the relationship between drugs and suicidal events (thoughts, attempts and completion) are discussed. Areas considered include analysis of spontaneous reporting system data, ecological trends in national and/or small area (e.g. county) suicide rates, meta-analyses of randomized clinical trials, and large-scale medical claims data. New statistical and experimental strategies for investigating possible associations between drugs and suicide are highlighted, and we suggest directions for future statistical/methodological research. To put this into context, we then review the most recent literature on the relationship between drugs (antidepressants, antiepileptics, varenicline, montelukast and antipsychotics) and suicidal events.

Overall, there appears to be little evidence that drugs increase the risk of suicide and related behaviour. Numerous lines of evidence in adults clearly demonstrate that inadequate treatment of depression (pharmacotherapy and/ or psychotherapy) is associated with increased risk of suicidal behaviour. In children, the results are less clear and further study is required to better delineate which children benefit from treatment and who may be at increased risk as a consequence of treatment. From a statistical and methodological perspective, the field of pharmacoepidemiology is a fertile area for statistical research, both in theory and in application. In general, methods have been adopted from other areas such as general epidemiology, despite the singular nature of many of the problems that are unique to drug safety in general, in particular the study of rare events. Finally, there is considerable debate concerning the communication of risk. For suicide, regulatory action has been taken largely on the basis of evidence suggesting increased risk of suicidal thoughts. However, suicidal thoughts are quite common, particularly among patients with depression, and may have little relationship to suicidal behaviour and/or completion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1

Similar content being viewed by others

References

  1. Goldsmith SK, Pellmar TC, Kleinman AM, et al. Reducing suicide: a national imperative. Washington, DC: The National Academies Press, 2002; 1–516

    Google Scholar 

  2. Brown CH, Wyman PA, Brinales JM, et al. The role or randomized trials in testing interventions for the prevention of youth suicide. Int J Psychiatry 2007; 19: 617–31

    Article  Google Scholar 

  3. Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990; 147: 207–10

    PubMed  CAS  Google Scholar 

  4. Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J Clin Psychiatry 1999; 60 Suppl. 2: 77–84

    Article  PubMed  CAS  Google Scholar 

  5. Goodwin FK, Fireman B, Simon GE, et al. Suicide risk in bipolar disorder during treatment with lithium and divalproex. J Am Med Assoc 2003; 290: 1467–73

    Article  CAS  Google Scholar 

  6. Thies-Flechtner K, Muller-Oerlinghausen B, Seibert W, et al. Effect of prophylactic treatment on suicide risk in patients with major affective disorders: data from a randomized prospective trial. Pharmacopsychiatry 1996; 29: 103–7

    Article  PubMed  CAS  Google Scholar 

  7. Tondo L, Jamison KR, Baldessarini RJ. Effect of lithium maintenance on suicidal behavior in major mood disorders. Ann N Y Acad Sci 1997; 836: 339–51

    Article  PubMed  CAS  Google Scholar 

  8. Tondo L, Baldessarini RJ, Hennen J, et al. Lithium treatment and risk of suicidal behavior in bipolar disorder patients. J Clin Psychiatry 1998; 59: 405–14

    Article  PubMed  CAS  Google Scholar 

  9. Tondo L, Hennen J, Baldessarini RJ. Lower suicide risk with long-term lithium treatment in major affective illness: a metaanalysis. Acta Psychiatr Scand 2001; 104: 163–72

    Article  PubMed  CAS  Google Scholar 

  10. Bowden RJ, Turkington DA. Instrumental variables. Cambridge: Cambridge University Press, 1984

    Google Scholar 

  11. Brodersen A, Licht RW, Vestergaard P, et al. Sixteen-year mortality in patients with affective disorder commenced on lithium. Br J Psychiatry 2000; 176: 429–33

    Article  PubMed  CAS  Google Scholar 

  12. Baldessarini RJ, Tondo L. Suicide risk and treatments for patients with bipolar disorder. J Am Med Assoc 2003; 290: 1517–9

    Article  CAS  Google Scholar 

  13. Isacsson G, Bergman U, Rich CL. Epidemiological data suggest antidepressants reduce suicide risk among depressives. J Affect Disord 1996; 41: 1–8

    Article  PubMed  CAS  Google Scholar 

  14. Markowitz JC. Antidepressants and suicide risk [letter]. Br J Psychiatry 2001; 178: 477

    Article  PubMed  CAS  Google Scholar 

  15. Ohberg A, Vuori E, Klaukka T, et al. Antidepressants and suicide mortality. J Affect Disord 1994; 50: 225–33

    Article  Google Scholar 

  16. Rich CL. Relationship between antidepressant treatment and suicide [letter]. J Clin Psychiatry 1999; 60: 340

    Article  PubMed  CAS  Google Scholar 

  17. Rihmer Z, Rutz W, Pihlgren H, et al. Decreasing tendency of seasonality in suicide may indicate lowering rate of depressive suicides in the population. Psychiatry Res 1998; 81: 233–40

    Article  PubMed  CAS  Google Scholar 

  18. Isacsson G. Suicide prevention: a medical breakthrough? Acta Psychiatr Scand 2000; 102: 113–7

    Article  PubMed  CAS  Google Scholar 

  19. Olfson M, Shaffer D, Marcus SC, et al. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 2003; 60: 978–82

    PubMed  Google Scholar 

  20. Hall WD, Mant A, Mitchell PB, et al. Association between antidepressant prescribing and suicide in Australia, 1991–2000: trend analysis. BMJ 2003; 326: 1008–12

    Article  PubMed  Google Scholar 

  21. Barbui C, Campomori A, D’Avanzo B, et al. Antidepressant drug use in Italy since the introduction of SSRIs: national trends, regional differences and impact on suicide rates. Soc Psychiatry Psychiatr Epidemiol 1999; 34: 152–6

    Article  PubMed  CAS  Google Scholar 

  22. Rutz W. Preventing suicide and premature death by education and treatment. J Affect Disord 2001; 62: 123–9

    Article  PubMed  CAS  Google Scholar 

  23. Grunebaum MF, Ellis SP, Li S, et al. Antidepressants and suicide risk in the United States, 1985–1999. J Clin Psychiatry 2004; 65(11): 1456–62

    Article  PubMed  Google Scholar 

  24. Isacsson G, Boëthius G, Bergman U. Low level of antidepressant prescription for people who later commit suicide: 15 years of experience from a population-based drug database in Sweden. Acta Psychiatr Scand 1992; 85: 444–8

    Article  PubMed  CAS  Google Scholar 

  25. Oquendo MA, Malone KM, Ellis SP, et al. Inadequacy of antidepressant treatment for patients with major depression who are at risk for suicidal behavior. Am J Psychiatry 1999; 156: 190–4

    PubMed  CAS  Google Scholar 

  26. Isometsä E, Henriksson M, Heikkinen M, et al. Suicide and the use of antidepressants: drug treatment of depression is inadequate [letter]. BMJ 1994; 308: 915

    Article  PubMed  Google Scholar 

  27. Henriksson S, Boethius G, Isacsson G. Suicides are seldom prescribed antidepressants: findings from a prospective prescription database in Jamtland county, Sweden, 1985–95. Acta Psychiatr Scand 2001; 103: 301–6

    Article  PubMed  CAS  Google Scholar 

  28. Blazer DG, Hybel CF, Simonsick EM, et al. Marked differences in antidepressant use by race in an elderly community sample: 1986–1996. Am J Psychiatry 2000; 157: 1089–94

    Article  PubMed  CAS  Google Scholar 

  29. Takahashi Y. Amidst a sharp increase of suicide: suicide in Japan. Tokyo: Kokoro no Kagaku (Nihon Hyoron-sha) 1999; 88: 2–10

    Google Scholar 

  30. Nakagawa A, Grunebaum MF, Ellis SP, et al. Suicide and antidepressant prescription rates in Japan, 1999–2003. J Clin Psychiatry 2007; 68: 908–16

    Article  PubMed  CAS  Google Scholar 

  31. Helgason T, Tomasson H, Zoega T. Antidepressants and public health in Iceland: time series analysis of national data. Br J Psychiatry 2004; 184: 157–62

    Article  PubMed  Google Scholar 

  32. Gibbons R, Hur K, Bhaumik D, et al. The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry 2005; 62: 165–72

    Article  PubMed  CAS  Google Scholar 

  33. Gibbons R, Hur K, Bhaumik D, et al. The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am J Psychiatry 2006; 163: 1898–904

    Article  PubMed  Google Scholar 

  34. Hammad T. Review and evaluation of clinical data 2004 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1-10-TAB08-Hammads-Review.pdf [Accessed 2011 Mar 1]

  35. Brent DA, Perper JA, Goldstein CE, et al. Risk factors for adolescent suicide: a comparison of adolescent suicide victims with suicidal inpatients. Arch Gen Psychiatry 1988; 45(6): 581–8

    Article  PubMed  CAS  Google Scholar 

  36. Shaffer D. Suicide: risk factors and the public health. Am J Public Health 1993; 83(2): 171–251

    Article  PubMed  CAS  Google Scholar 

  37. Leon AC, Marzuk PM, Tardiff K, et al. Paroxetine, other antidepressants, and youth suicide in New York City: 1993 through 1998. J Clin Psychiatry 2004; 65: 915–8

    Article  PubMed  Google Scholar 

  38. Isacsson G, Holmgren P, Ahlner J. Selective serotonin reuptake inhibitor antidepressants and the risk of suicide: a controlled forensic database study of 14,857 suicides. Acta Psychiatr Scand 2005; 111: 286–90

    Article  PubMed  CAS  Google Scholar 

  39. Gray D, Moskos M, Keller T. Utah Youth Suicide Study new findings. Presented at the Annual Meeting of the American Association of Suicidology; 2003 Apr 23–26; Santa Fe

  40. Anderson RN. Deaths: leading causes for 2000. National Vital Statistics Reports. Hyattsville (MD): National Center for Health Statistics 2002; 50(16): 1–48

  41. Grunbaum JA, Kann L, Kinchen SA, et al. Youth risk behavior surveillance: United States, 2001. MMWR Surveill Summ 2002; 51: 1–62

    PubMed  Google Scholar 

  42. Fombonne E, Wostear G, Cooper V, et al. The Maudsley long-term follow-up of child and adolescent depression; 2, suicidality, criminality and social dysfunction in adulthood. Br J Psychiatry 2001; 179: 218–23

    Article  PubMed  CAS  Google Scholar 

  43. Weissman MM, Wolk S, Goldstein RB, et al. Depressed adolescents grown up. J Am Med Assoc 1999; 281: 1707–13

    Article  CAS  Google Scholar 

  44. Kovacs M, Goldston D, Gatsonis C. Suicidal behaviors and childhood-onset depressive disorders: a longitudinal investigation. J Am Acad Child Adolesc Psychiatry 1993; 32: 8–20

    Article  PubMed  CAS  Google Scholar 

  45. Rao U, Weissman MM, Martin JA, et al. Childhood depression and risk of suicide: a preliminary report of a longitudinal study. J Am Acad Child Adolesc Psychiatry 1993; 32: 21–7

    Article  PubMed  CAS  Google Scholar 

  46. Hazell P, O’Connell D, Heathcote D, et al. Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev 2002; (2): CD002317

  47. Treatment for Adolescents with Depression Study (TADS) Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. J Am Med Assoc 2004; 292: 807–20

    Article  Google Scholar 

  48. Mann JJ, Emslie G, Baldessarini RJ, et al. ACNP Task Force report on SSRIs and suicidal behavior in youth. Neuropsychopharmacology 2005; 31: 473–92

    Article  CAS  Google Scholar 

  49. Emslie GJ, Rush AJ, Weinberg WA. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997; 54: 1031–7

    Article  PubMed  CAS  Google Scholar 

  50. Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment. JAMA 2007; 297: 1683–96

    Article  PubMed  CAS  Google Scholar 

  51. Gibbons R, Brown CH, Hur K, et al. Early evidence on the effects of the FDA black box warning on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007; 164: 1356–63

    Article  PubMed  Google Scholar 

  52. Valuck RJ, Libby AM, Sills MR, et al. Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: a propensity-adjusted retrospective cohort study. CNS Drugs 2004; 18: 1119–32

    Article  PubMed  CAS  Google Scholar 

  53. Simon GE, Savarino J, Operskalski B. Suicide risk during antidepressant treatment. Am J Psychiatry 2006; 163: 41–7

    Article  PubMed  Google Scholar 

  54. Olfson M, Marcus SC, Shaffer D. Antidepressant drug therapy and suicide in severely depressed children and adults. Arch Gen Psychiatry 2006; 63: 865–72

    Article  PubMed  Google Scholar 

  55. Tiihonen J, Lönnqvist J, Wahlbeck K, et al. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry 2006; 63: 1358–67

    Article  PubMed  CAS  Google Scholar 

  56. World Health Organization. Suicide prevention and special programmes (2003) [online]. Available from URL: http://www.who.int/mental_-health/prevention/suicide/country_reports/en/ [Accessed 2011 Mar 1]

  57. De Leo D, Dwyer J, Firman D, et al. Trends in hanging and firearm suicide rates in Australia: substitution of method? Suicide Life Threat Behav 2003; 33: 151–64

    Article  PubMed  Google Scholar 

  58. DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA Spontaneous Reporting System. Am Stat 1999; 53: 177–90

    Google Scholar 

  59. DuMouchel W, Pregibon D. Empirical Bayes screening for multi-item association. Proceedings of the Seventh ACM SIGKDD International Conference on Knowledge Discovery and Data Mining; 2001 Aug 26–29; San Francisco (CA), 67–76

  60. Sonesson C, Bock D. A review and discussion of prospective statistical surveillance in public health. J Royal Stat Soc A 2003; 166: 5–21

    Article  Google Scholar 

  61. Gibbons RD, Segawa E, Karabatsos G, et al. Mixed-effects Poisson regression analysis of adverse event reports: the relationship between antidepressants and suicide. Stat Med 2008; 27: 1814–33

    Article  PubMed  Google Scholar 

  62. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006; 63: 332–9

    Article  PubMed  CAS  Google Scholar 

  63. Huber PJ. The behavior of maximum likelihood estimates under nonstandard conditions. Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability; 1965 Jun 21–Juy 18; Berkeley (CA). Vol 1. Berkeley (CA): University of California Press, 1967: 221–33

    Google Scholar 

  64. White H. A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. Econometrica 1980; 48: 817–30

    Article  Google Scholar 

  65. White H. Maximum likelihood estimation of misspecified models. Econometrica 1982; 50: 1–25

    Article  Google Scholar 

  66. Ludwig J, Marcotte D. Anti-depressants, suicide and drug regulation. J Policy Anal Manage 2005; 24: 249–72

    Article  PubMed  Google Scholar 

  67. Hedeker D, Gibbons RD. Longitudinal data analysis. New York: Wiley, 2006

    Google Scholar 

  68. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–88

    Article  PubMed  CAS  Google Scholar 

  69. Malzahn U, Bohning D, Holling H. Nonparametric estimation of heterogeneity variance for the standardized difference used in meta-analysis. Biometrika 2000; 87: 619–32

    Article  Google Scholar 

  70. Sidik K, Jonkman JN. Simple heterogeneity variance estimation for meta-analysis. Appl Stat (J Royal Stat Soc, Series C) 2005; 54: 367–84

    Article  Google Scholar 

  71. Sidik K, Jonkman JN. A comparison of heterogeneity variance estimators in combining results of studies. Stat Med 2007; 26: 1964–81

    Article  PubMed  Google Scholar 

  72. Hardy RJ, Thompson SG. Detecting and describing heterogeneity in meta-analysis. Stat Med 1998; 17: 841–56

    Article  PubMed  CAS  Google Scholar 

  73. Mittlboeck M, Heinzl H. A simulation study comparing properties of heterogeneity measures in meta-analyses. Stat Med 2006; 25: 4321–33

    Article  Google Scholar 

  74. Rosenbaum P, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41–50

    Article  Google Scholar 

  75. Gibbons RD, Hur K, Brown CH, et al. The relationship between antiepileptics and suicide attempts in patients with bipolar disorder. Arch Gen Psychiatry 2009; 66: 1354–60

    Article  PubMed  CAS  Google Scholar 

  76. Gibbons RD, Amatya AK, Brown CH, et al. Post-approval drug safety surveillance. Ann Rev Pub Health. 2010; 31: 419–37

    Article  Google Scholar 

  77. Rosenbaum PR. Differential effects and generic biases in observational studies. Biometrika 2006; 93: 573–86

    Article  Google Scholar 

  78. Efron B. Logistic regression, survival analysis, and the Kaplan Meier curve. J Am Stat Assoc 1988; 83: 414–25

    Article  Google Scholar 

  79. Gibbons RD, Duan N, Meltzer D, et al. Waiting for organ transplantation: results of an analysis by Institute of Medicine Committee. Biostatistics 2003; 4: 207–22

    Article  PubMed  Google Scholar 

  80. Posner K, Oquendo MA, Gould M, et al. Columbia classification algorithm of suicide assessment (C-CASA): classification of suicidal events in the FDA’s pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 2007; 164: 1035–43

    Article  PubMed  Google Scholar 

  81. Gibbons RD, Brown CH, Hur K, et al. The relationship between antidepressants and suicide: results of analysis of the Veterans Health Administration datasets. Am J Psychiatry 2007; 164: 1044–9

    Article  PubMed  Google Scholar 

  82. US Food and Drug Administration. Clinical review: relationship between antidepressant drugs and suicidality in adults [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf [Accessed 2011 Mar 25]

  83. Pamer CA, Hammad TA, Wu YT, et al. Changes in US antidepressant and antipsychotic prescription patterns during a period of FDA actions. Pharmacoepidemiol Drug Saf 2010; 19: 158–74

    Article  PubMed  Google Scholar 

  84. Rosack J. New data show declines in antidepressant prescribing. Psychiatr News 2005; 40: 1–6

    Google Scholar 

  85. Nemeroff CB, Kalali A, Keller MB, et al. Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch Gen Psychiatry 2007; 64: 466–72

    Article  PubMed  Google Scholar 

  86. Centers for Disease Control and Prevention. Suicide trends among youths and young adults aged 10–24 years United States, 1990–2004. Morbidity and Mortality Weekly Review 2007; 56: 905–8

    Google Scholar 

  87. Libby AM, Brent DA, Morrato EH, et al. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. Am J Psychiatry 2007; 164: 884–91

    Article  PubMed  Google Scholar 

  88. Libby AM, Orton H, Valuck RJ. Persisting decline in depression treatment after FDA warnings. Arch Gen Psychiatry 2009; 66: 633–9

    Article  PubMed  Google Scholar 

  89. Wheeler BW, Gunnell D, Metcalfe C, et al. The population impact on incidence of suicide and non-fatal self harm of regulatory action against the use of selective serotonin reuptake inhibitors in under 18s in the United Kingdom: ecological study. BMJ 2008; 336: 542–7

    Article  PubMed  Google Scholar 

  90. FDA 8/28/2009. Statistical review and evaluation: anti-epileptic drugs and suicidality [online]. Available from URL: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm166246.htm [Accessed 2008 May 23]

  91. Goodwin FK, Fireman B, Simon GE, et al. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003; 290: 1467–73

    Article  PubMed  CAS  Google Scholar 

  92. Collins JC, McFarland BH. Divalproex, lithium, and suicide among Medicaid patients with bipolar disorder. J Affect Disorder 2008; 107: 23–8

    Article  CAS  Google Scholar 

  93. Arana A, Wentworth CE, Ayuso-Mateos JL, et al. Suicide-related events in patients treated with antiepileptic drugs. N Engl J Med 2010; 363: 542–51

    Article  PubMed  CAS  Google Scholar 

  94. Gibbons RD, Hur K, Brown CH, et al. Gabapentin and suicide attempts. Pharmacoepidemiol Drug Saf 2010; 19: 1241–7

    Article  PubMed  CAS  Google Scholar 

  95. Patorno E, Bohn RL, Wahl PM, et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA 2010; 303: 1401–9

    Article  PubMed  CAS  Google Scholar 

  96. Marcus S. Using omitted variable bias to assess uncertainty in the estimation of an AIDS education treatment effect. J Ed Behav Stat 1997; 22: 193–201

    Google Scholar 

  97. Olesen JB, Hansen PR, Erdal J, et al. Antiepileptic drugs and risk of suicide: a national study. Pharmacoepidemiol Drug Saf 2010; 19: 518–24

    PubMed  Google Scholar 

  98. VanCott AC, Cramer JA, Copeland LA, et al. Suicide-related behaviors in older patients with new anti-epileptic drug use: data from the VA hospital system. BMC Med 2010; 8: 1–7

    Article  Google Scholar 

  99. Bisgaard H, Skoner D, Boza ML, et al. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. Pediatr Pulmonol 2009; 44: 568–79

    Article  PubMed  Google Scholar 

  100. Holbrook JT, Harik-Khan R. Montelukast and emotional well-being as a marker for depression: results from 3 randomized, double-masked clinical trials. J Allergy Clin Immunol 2008; 122: 828–9

    Article  PubMed  Google Scholar 

  101. Jick H, Hagberg KW, Egger P. Rate of suicide in patients taking montelukast. Pharmacotherapy 2009; 29: 165–6

    Article  PubMed  Google Scholar 

  102. Goodwin RD, Eaton WW. Asthma, suicidal ideation, and suicide attempts: findings from the Baltimore epidemiologic catchment area follow-up. Am J Public Health 2005; 95: 717–22

    Article  PubMed  Google Scholar 

  103. Hughes JR. Smoking and suicide: a brief overview. Drug Alcohol Depend 2008; 98: 169–78

    Article  PubMed  Google Scholar 

  104. Hays JT, Ebert JO. Varenicline for tobacco dependence. N Engl JMed 2008; 359: 2018–24

    Article  CAS  Google Scholar 

  105. Gunnell D, Irvine D, Wise L, et al. Varenicline and suicidal behavior: a cohort study based on data from the General Practice Research Database. BMJ 2009; 339: b3805

    Article  PubMed  CAS  Google Scholar 

  106. Hemmingsson T, Kriebel D. Smoking at age 18–20 and suicide during 26 years of follow-up: how can the association be explained? Int J Epidemiol 2003; 32: 1000–4

    Article  PubMed  Google Scholar 

  107. Miller M, Hemenway D, Rimm E. Cigarettes and suicide: a prospective study of 50 000 men. Am J Public Health 2000; 90: 768–73

    Article  PubMed  CAS  Google Scholar 

  108. Cahill K, Stead L, Lancaster T. A preliminary benefit-risk assessment of varenicline in smoking cessation. Drug Saf 2009; 32: 119–35

    Article  PubMed  CAS  Google Scholar 

  109. Nides M, Oncken C, Gonzalez D, et al. Smoking cessation with varenicline, a selective a4b2 nicotinic receptor partial agonist. Arch Intern Med 2006; 166: 1561–8

    Article  PubMed  Google Scholar 

  110. Keating GM, Siddiqui MA. Varenicline: a review of its use as an aid to smoking cessation therapy. CNS Drugs 2006; 20: 945–60

    Article  PubMed  CAS  Google Scholar 

  111. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an a4×2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation. JAMA 2006; 296(1): 56–63

    Article  PubMed  CAS  Google Scholar 

  112. Oncken C, Gonzalez D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist varenicline, for smoking cessation. Arch Intern Med 2006; 166: 1571–7

    Article  PubMed  CAS  Google Scholar 

  113. Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006; 296: 64–71

    Article  PubMed  CAS  Google Scholar 

  114. Kasliwal R, Wilton LV, Shakir SAW. Safety and drug utilization profile of varenicline as used in general practice in England. Drug Saf 2009; 32: 499–507

    Article  PubMed  CAS  Google Scholar 

  115. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia. Arch Gen Psychiatry 2003; 60: 82–91

    Article  PubMed  CAS  Google Scholar 

  116. Khan A, Khan SR, Leventhal RM, et al. Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the Food and Drug Administration database. Am J Psychiatry 2001; 158: 1449–54

    Article  PubMed  CAS  Google Scholar 

  117. Herings RM, Erkens JA. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Saf 2003; 12: 423–4

    Article  PubMed  Google Scholar 

  118. Montgomery SA, Montgomery DB, Rani SJ, et al. Maintenance therapy in repeat suicidal behaviour: a placebo-controlled trial. Proceedings of the Xth International Congress for Suicide Prevention and Crisis Intervention; 1979 June 17–20; Ottawa (ON), 227–9

  119. Soloff PH, Lis JA, Kelly T, et al. Self-mutilation and suicidal behavior in borderline personality disorder. J Personal Disord 1994; 8: 257–67

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported by NIMH grants R01 MH8012201 (R.D. Gibbons) and MH062185 (J.J. Mann). Dr Gibbons has served as an expert witness for the US Department of Justice, Wyeth and Pfizer Pharmaceuticals on suicide-related cases. Dr Mann has received research support from GlaxoSmithKline and Novartis for unrelated brain imaging studies.

Author information

Authors and Affiliations

  1. Departments of Medicine and Health Studies, and the Center for Health Statistics, University of Chicago, 5841 S. Maryland Avenue, MC 2007 Office W260, Chicago, Illinois, 60637, USA

    Robert D. Gibbons (Director)

  2. Department of Molecular Imaging and Neuropathology, New York State Psychiatric Institute, New York, New York, USA

    J. John Mann

  3. Department of Psychiatry, Columbia University College of Physicians & Surgeons, New York, New York, USA

    J. John Mann

Authors
  1. Robert D. Gibbons
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. John Mann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert D. Gibbons.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gibbons, R.D., Mann, J.J. Strategies for Quantifying the Relationship between Medications and Suicidal Behaviour. Drug-Safety 34, 375–395 (2011). https://doi.org/10.2165/11589350-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11589350-000000000-00000

Keywords

Search

Navigation